Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK‐positive NSCLC from a phase II study
暂无分享，去创建一个
W. Feng | K. Ma | G. Selvaggi | W. Zhong | Jianya Zhou | Yong Song | Li Zhang | Lejie Cao | Yang Wang | Zhilin Shen | L. Ding | Yunpeng Liu | Shijun Zhao | Gang Wu | S. Xiao | Jing Zheng | F. Ye | Tao Wang | J. Fang | Huijie Wang | Qian Wang | Jianying Zhou | Shundong Cang | Zhuang Wu | Zhendong Zheng | Yunpeng Yang | Jifeng Feng | Chengzhi Zhou | Jun Zhao | Yanqiu Zhao | Youling Gong | Yun Fan | Jianhua Chen | Shucai Zhang | Yuan Chen | Wei Song | Yiping Zhang | Jie Huang | Yi Hu | Zhuang Yu | Yubiao Guo | Gaofeng Li | Ning Wu | Xiaoqing Liu